277 related articles for article (PubMed ID: 22447230)
21. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
Levy AP; Blum S
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1105-11. PubMed ID: 18035926
[TBL] [Abstract][Full Text] [Related]
22. Structure-function analysis of the antioxidant properties of haptoglobin.
Melamed-Frank M; Lache O; Enav BI; Szafranek T; Levy NS; Ricklis RM; Levy AP
Blood; 2001 Dec; 98(13):3693-8. PubMed ID: 11739174
[TBL] [Abstract][Full Text] [Related]
23. Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome.
Lavie L; Lotan R; Hochberg I; Herer P; Lavie P; Levy AP
Sleep; 2003 Aug; 26(5):592-5. PubMed ID: 12938813
[TBL] [Abstract][Full Text] [Related]
24. The Haptoglobin genotype predicts cardio-renal mortality in type 1 diabetes.
Costacou T; Orchard TJ
J Diabetes Complications; 2016 Mar; 30(2):221-6. PubMed ID: 26684170
[TBL] [Abstract][Full Text] [Related]
25. Haptoglobin phenotype and vascular complications in patients with diabetes.
Levy AP; Roguin A; Hochberg I; Herer P; Marsh S; Nakhoul FM; Skorecki K
N Engl J Med; 2000 Sep; 343(13):969-70. PubMed ID: 11012324
[No Abstract] [Full Text] [Related]
26. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy.
Levy AP
Pharmacol Ther; 2006 Nov; 112(2):501-12. PubMed ID: 16854468
[TBL] [Abstract][Full Text] [Related]
27. Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques.
Lioupis C; Barbatis C; Drougou A; Koliaraki V; Mamalaki A; Klonaris C; Georgopoulos S; Andrikopoulos V; Bastounis E
Atherosclerosis; 2011 May; 216(1):131-8. PubMed ID: 21316675
[TBL] [Abstract][Full Text] [Related]
28. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease.
Asleh R; Marsh S; Shilkrut M; Binah O; Guetta J; Lejbkowicz F; Enav B; Shehadeh N; Kanter Y; Lache O; Cohen O; Levy NS; Levy AP
Circ Res; 2003 Jun; 92(11):1193-200. PubMed ID: 12750308
[TBL] [Abstract][Full Text] [Related]
29. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype.
Blum S; Milman U; Shapira C; Miller-Lotan R; Bennett L; Kostenko M; Landau M; Keidar S; Levy Y; Khemlin A; Radan A; Levy AP
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):e18-20. PubMed ID: 18296583
[No Abstract] [Full Text] [Related]
30. [Diabetes mellitus and cardiovascular system diseases in middle age].
Efimov AS; Gordienko VM; Slavnov VN; Sviatelik GV; Kaminskiĭ LA
Kardiologiia; 1977 Nov; 17(11):133-9. PubMed ID: 599811
[TBL] [Abstract][Full Text] [Related]
31. Haptoglobin genotype and diabetic microangiopathies in Japanese diabetic patients.
Koda Y; Soejima M; Yamagishi S; Amano S; Okamoto T; Inagaki Y; Yamada K; Kimura H
Diabetologia; 2002 Jul; 45(7):1039-40. PubMed ID: 12187922
[No Abstract] [Full Text] [Related]
32. Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients.
Burbea Z; Nakhoul F; Zoabi R; Hochberg I; Levy NS; Benchetrit S; Weissgarten J; Tovbin D; Knecht A; Iaina A; Herman M; Kristal B; Levy AP
Ann Clin Biochem; 2004 Nov; 41(Pt 6):469-73. PubMed ID: 15588436
[TBL] [Abstract][Full Text] [Related]
33. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus.
Miller-Lotan R; Herskowitz Y; Kalet-Litman S; Nakhoul F; Aronson D; Zoabi R; Asaf R; Ben-Izhak O; Sabo E; Lim SK; Baumann H; Berger FG; Levy AP
Diabetes Metab Res Rev; 2005; 21(4):332-7. PubMed ID: 15852445
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008.
Laakso M
Diabetes Care; 2010 Feb; 33(2):442-9. PubMed ID: 20103560
[No Abstract] [Full Text] [Related]
35. Is there a relationship between genetically determined haptoglobin phenotype and insulin-dependent diabetes mellitus (IDDM)?
Ratzmann KP; Strese J; Keilacker H; Giebelmann R; Scheibe F; Witt S
Exp Clin Endocrinol; 1984 Apr; 83(2):207-15. PubMed ID: 6539222
[TBL] [Abstract][Full Text] [Related]
36. Haptoglobin: basic and clinical aspects.
Levy AP; Asleh R; Blum S; Levy NS; Miller-Lotan R; Kalet-Litman S; Anbinder Y; Lache O; Nakhoul FM; Asaf R; Farbstein D; Pollak M; Soloveichik YZ; Strauss M; Alshiek J; Livshits A; Schwartz A; Awad H; Jad K; Goldenstein H
Antioxid Redox Signal; 2010 Feb; 12(2):293-304. PubMed ID: 19659435
[TBL] [Abstract][Full Text] [Related]
37. [Genetic risk factors for diabetic complications].
Deutsch E; Vardi P; Shohat M
Harefuah; 1997 Jun; 132(12):862-6. PubMed ID: 9264195
[No Abstract] [Full Text] [Related]
38. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
Blum S; Vardi M; Brown JB; Russell A; Milman U; Shapira C; Levy NS; Miller-Lotan R; Asleh R; Levy AP
Pharmacogenomics; 2010 May; 11(5):675-84. PubMed ID: 20415560
[TBL] [Abstract][Full Text] [Related]
39. The two faces of miR-29.
Ślusarz A; Pulakat L
J Cardiovasc Med (Hagerstown); 2015 Jul; 16(7):480-90. PubMed ID: 25689084
[TBL] [Abstract][Full Text] [Related]
40. [Possible genetic causes for late complications of diabetes mellitus].
Klemm T; Paschke R
Med Klin (Munich); 2000 Jan; 95(1):31-9. PubMed ID: 10668342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
